Clinical Study of 68GA-labeled Claudin 18.2 Developer Combined with PET/CT for Imaging of Gastric or Gastroesophageal Junction Adenocarcinoma and Pancreatic Cancer
Trial ID: NCT06646783
Interventional - Phase 1 - Not yet recruiting
68Ga labeled Claudin 18.2 contrast agent combined with PET/CT for gastric or gastroesophageal junction
Conditions
Adenocarcinoma of the Stomach
Adenocarcinoma of GE Junction
Pancreatic Cancer Stage
Interventions
[68Ga]Ga-NODAGA-SNA014
Eligibility
Inclusion criteria
- Age range of 18 to 75 years old (including boundary values);
Individuals with behavioral capacity who voluntarily participate in this clinical study and sign an informed consent form (ICF);
Diagnosed G/GEJ adenocarcinoma and pancreatic cancer;
Gastroscopy/CT/MRI/PET-CT examination results within the past month (if any);
Pathological test results and Claudin18.2 immunohistochemistry results within the past year (if available).
Exclusion criteria
- Merge patients with other clearly diagnosed malignant tumors:
Uncontrolled severe infections or individuals with other serious illnesses;
Those with an expected survival period of less than or equal to three months;
Pregnant or lactating patients, as well as reproductive age patients who refuse to take appropriate contraceptive measures during this trial;
investigators determine that patients who are not suitable to participate in this study;